ORIGINAL RESEARCH article

Front. Nutr., 14 August 2025

Sec. Nutritional Epidemiology

Volume 12 - 2025 | https://doi.org/10.3389/fnut.2025.1621277

Association of the newly proposed dietary index for gut microbiota and all-cause and cardiovascular mortality among individuals with diabetes and prediabetes

  • 1. Department of Laboratory Medicine, The First Affiliated Hospital, Wannan Medical College, Wuhu, Anhui, China

  • 2. Department of Nephrology, The First Affiliated Hospital, Wannan Medical College, Wuhu, Anhui, China

Article metrics

View details

1

Citations

3,7k

Views

486

Downloads

Abstract

Background:

The Gut Microbiota Dietary Index (DI-GM) is a newly developed assessment tool that quantitatively evaluates the nutritional modulation of intestinal microbial communities through systematic characterization of diet-microbiome interactions. The relationship between DI-GM and the risk of death has not been elucidated in patients with diabetes or prediabetes. The present cohort study examined the longitudinal relationship between DI-GM scores and both overall mortality and mortality from cardiovascular disease in this clinically vulnerable population.

Method:

The investigation used data from the National Health and Nutrition Examination Survey (NHANES) 2007–2018. Analytical approaches, including multivariable-adjusted Cox proportional hazards regression, restricted cubic spline (RCS) modeling, stratified subgroup evaluations, and sensitivity assessments, were employed to examine the relationships linking DI-GM scores to mortality outcomes among individuals with diabetes or prediabetes.

Result:

During an average monitoring duration of 77.39 months within the cohort of 8,409 participants, 1,430 fatalities from all causes were documented, including 381 cases attributed to cardiovascular events. Multivariable-adjusted Cox regression analyses showed a negative correlation, with a 1-unit increase in DI-GM corresponding to an 8% lower all-cause mortality risk (HR = 0.92, 95% CI: 0.89–0.95; p < 0.001) and an 11% reduction in cardiovascular-specific mortality (HR = 0.89, 95% CI: 0.83–0.95; p < 0.001). When comparing extreme quartiles of DI-GM distribution, participants in the highest quartile exhibited 26% lower all-cause mortality (HR = 0.74, 95% CI: 0.63–0.87; p < 0.001; trend p < 0.05) and 30% lower cardiovascular mortality (HR = 0.70, 95% CI: 0.52–0.96; p = 0.025; trend p < 0.05) than those in the lowest quartile. Subgroup analyses confirmed the consistency of the results in most categories. Restricted cubic splines demonstrated negative correlations between DI-GM and both mortality outcomes. The Beneficial Gut Microbiota Score (BGMS) exhibited inverse associations with mortality risks, while the Unfavorable Gut Microbiota Score (UGMS) showed no significant relationship. In the sensitive analysis, the robustness of multiple interpolation results was verified by deleting missing data.

Conclusion:

Among patients with diabetes or prediabetes, elevated DI-GM levels were negatively correlated with all-cause mortality and cardiovascular mortality risks.

Introduction

Diabetes is a major public health challenge worldwide. From 1990 to 2021, global diabetes prevalence increased threefold, with projections indicating over 1.3 billion affected individuals by 2025 if uncontrolled (1). According to diagnostic criteria established by the American Diabetes Association (ADA), diabetes mellitus is classified as a persistent metabolic disorder that is diagnostically confirmed through sustained hyperglycemia (defined as fasting plasma glucose ≥ 7.0 mmol/L) or elevated glycosylated hemoglobin (HbA1c) levels ≥ 6.5%, pathophysiologically rooted in a disorder of insulin production or cellular responsiveness (2). Prediabetes, a transitional phase between normal glucose regulation and diabetes, affects approximately 720 million people globally (3, 4). Cardiovascular disease, which is strongly linked to diabetes, contributes to over 50% of mortality in this population (5). Epidemiological investigations have consistently established that individuals with diabetes or prediabetes have significantly heightened risks for both all-cause mortality and cardiovascular-specific fatality outcomes (6–8).

Gut microbial composition and functionality exert critical influences on diabetes pathogenesis (9, 10). The gut microbiome can influence systemic inflammation, insulin sensitivity and energy balance through various mechanisms, such as the fermentation of dietary fiber, the production of short-chain fatty acids (SCFA), and the regulation of gut-brain signaling (11–13). A substantial corpus of research has demonstrated that individuals with diabetes or prediabetes have a reduced abundance and functional capacity of bacteria which produce butyrate (14). Dietary factors, particularly fiber intake, strongly regulate butyrate-producing microbial populations, potentially enhancing glycemic control (15). Nutritional patterns are the primary determinants of gut microbiome structure (15). Evidence indicates that dietary-derived microbial metabolites positively modulate insulin secretion, sensitivity, and diabetes incidence (16–19). Dietary modifications alter host microbial communities, cardiometabolic profiles, and immune responses through interconnected pathways (20). Epidemiological studies have confirmed that a nutritionally imbalanced dietary structure characterized by excessive intake of red meat and processed meat products, alcohol abuse, frequent consumption of refined carbohydrates (such as white bread), and sugar-added beverages has a significant dose-dependent association with the prediabetes state and the risk of diagnosed diabetes (21, 22).

Many studies have examined the effects of individual dietary components and their impact on gut microbiota (23, 24). According to Kase et al., the DI-GM was developed based on a large number of literature reviews and indicated that DI-GM is related to indirect biomarkers of intestinal microbiota diversity (25). The DI-GM aims to quantify the effects of nutritional patterns on the structure and metabolic characteristics of the gut microbiome by systematically evaluating the interaction between diet and microbiome. Based on a large number of review articles, 14 types of foods and nutrients have been determined to have beneficial or adverse effects on the gut microbiota. Compared with HEI-2015 and the Mediterranean Diet Score (MDS), the DI-GM focuses on a broader range of gut microbiome attributes (for example, the production of short-chain fatty acids (SCFA), changes in microbiota phyla, and specific bacterial species), providing a more comprehensive assessment of diet-microbiome relationships (25, 26). Malesza et al.‘s research indicates that a high-fat diet is associated with reduced microbial richness and increased intestinal permeability (27). A high-fat diet rich in meat protein may promote different and less diverse populations of sulfur-metabolizing bacteria (28). Recent studies have shown a negative relationship between DI-GM and the risk of developing diabetes (29). In addition, the incidence of other diseases associated with DI-GM, such as stroke (30), chronic kidney disease (31), and depression (32), is negatively correlated. Despite growing evidence on gut microbiota-diet interactions, the longitudinal associations linking the DI-GM to mortality risk in individuals with diabetes or prediabetes have not been fully established. The purpose of our study was to systematically evaluate the prognostic value of DI-GM for all-cause mortality and cardiovascular-specific mortality endpoints in a high-risk population using the NHANES data system.

Method

Population

The investigation used data from the NHANES. The survey’s core mission focuses on tracking health status and nutritional parameters among non-institutionalized civilian residents of the United States through three-tiered data collection: standardized in-home questionnaires, comprehensive physical examinations at Mobile Examination Centers (MECs), and biochemical assays conducted in certified laboratories, all implemented via a complex multistage probability cluster sampling design. All study protocols received ethical approval from the NCHS Institutional Review Board, with written informed consent secured from each participant prior to data collection. The analytical cohort initially comprised 59,842 individuals drawn from six consecutive NHANES cycles spanning 2007–2018, with data retrieved from the official NHANES repository. We excluded the following individuals: (1) age <20 years at baseline (n = 25,072); (2) absence of confirmed diabetes or prediabetes diagnosis (n = 25,496); (3) incomplete mortality follow-up (n = 17); (4) lack of complete DI-GM measurements (n = 848). The final analytical cohort comprised 8,409 eligible individuals (Figure 1).

Figure 1

Flowchart detailing participant selection from NHANES 2007-2018 data. Initially 59,842 participants, 25,072 under 20 years excluded. Remaining 34,770 screened; 25,496 without diabetes or prediabetes excluded. Of 9,274 eligible, 865 with missing data excluded, leaving 8,409 for final analysis.

Screening process of participants.

Definition of diabetes and prediabetes

Diabetes diagnosis was determined by meeting ≥1 of these parameters: (1) elevated fasting plasma glucose (FPG ≥ 7.0 mmol/L) or 2-h oral glucose tolerance test (2 h-OGTT) ≥ 11.1 mmol/L; (2) glycated hemoglobin (HbA1c) ≥ 6.5%; (3) random blood glucose ≥ 11.1 mmol/L; (4) your doctor has diagnosed you with diabetes or you are currently using insulin.

Prediabetes classification required fulfillment of ≥ 1 criterion: (1) 2 h-OGTT results 7.8–11.0 mmol/L; (2) HbA1c 5.7–6.4%; (3) FPG 6.1–6.9 mmol/L; (4) a physician’s diagnosis of prediabetes.

Dietary index of gut microbiota

The Dietary Index of Gut Microbiota (DI-GM) was developed to evaluate how diet influences the composition of the gut microbiome through literature-derived parameters (25). The index was derived from two 24-h dietary recall datasets, with the average value of these datasets being calculated. The initial data pertaining to the recall were collated at the MEC, while subsequent data were obtained through the medium of telephone interviews. To ensure data quality, the NHANES implemented standardized interviewer training protocols with validated assessment tools, effectively minimizing measurement errors related to recall bias and interviewer variability. The DI-GM scoring system evaluates 14 dietary components categorized into two groups: health-promoting constituents (fermented dairy products, soybeans, chickpeas, fiber, cranberries, avocados, broccoli, coffee, tea, and whole grains,) and detrimental elements (refined cereals, unprocessed/processed red meats, and high-fat diets [≥ 40% total energy intake]). Specific tea varieties were excluded due to insufficient granularity in NHANES dietary records. Scoring criteria were defined as follows: beneficial components received 1 point when intake met or exceeded sex-stratified median values, otherwise 0; detrimental components scored 1 point when consumption fell below sex-specific medians (or < 40% energy from fat for high-fat diets), otherwise 0. The composite DI-GM scale ranges from 0–13 points and comprising two subscales: beneficial (0–9) and detrimental (0–4) components. Higher aggregate scores reflected stronger microbiota-friendly dietary profiles. For analytical purposes, the participants were stratified into quartiles based on DI-GM scores. The complete scoring criteria and food classifications are provided in Supplementary Table 1.

Covariant

The covariates considered in the present study included age, gender, race/ethnicity, educational attainment, marital status, family poverty income ratio (PIR), body mass index (BMI), smoking, alcohol consumption, hypertension, physical activity, coronary heart disease, stroke, cancer, insulin usage status and total cholesterol. Educational attainment was categorized into three categories: below high school, high school, and beyond high school. The classification of ethnicity included the categories Mexican-American, other Hispanic, non-Hispanic Asian, non-Hispanic White people, non-Hispanic Black, and other races. Marital status was dichotomized into married/cohabiting partnerships and unmarried status (encompassing widowed, separated, and divorced individuals). Body mass index (BMI) was stratified according to WHO criteria: normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), and obese (≥ 30.0 kg/m2). Poverty-income ratios were categorized into three tiers: ≤ 1.0 (below the poverty line), 1.1–3.0 (low-moderate income), and ≥ 3.1 (higher socioeconomic status). Smoking was categorized into three categories: individuals who have never smoked, those who used to smoke but have quit smoking, and current smokers. Alcohol consumption patterns were operationalized as: abstainers (< 12 lifetime drinks or ≥12 drinks without past-year consumption), low to moderate drinkers (women ≤ 1 drink/day; men ≤ 2 drinks/day), and heavy drinkers (women > 1 drink/day; men > 2 drinks/day). Clinically confirmed hypertension was defined as self-reported physician diagnosis. According to previous studies, physical activity is divided into low physical activity (<500 MET/wk) and high physical activity (≥ 500 MET/wk) (33). The insulin usage status was categorized as either using or not using. Coronary heart disease: Being informed that one has coronary heart disease. Stroke: Being informed that one has had a stroke. Cancer: Being informed that one has had cancer or a malignant tumor.

Mortality assessment

Mortality outcomes were ascertained through linkage with the National Death Index (NDI), a federal mortality registry maintained by the National Center for Health Statistics (NCHS). The observational window spanned from study enrollment through December 31, 2019, capturing complete mortality surveillance data1. Cause-specific mortality classifications adhered to ICD-10 coding protocols. All-cause mortality aggregated all documented fatalities, including but not limited to cardiovascular pathologies (ICD-10 I00-I78), neoplastic disorders (C00-C97), accidental trauma (V01-X59), cerebrovascular events (I60-I69), diabetes-related complications (E10-E14), and other etiologies. Cardiovascular mortality specifically included fatal diseases of the cardiovascular system. The follow-up duration was determined as the period between baseline evaluation and either mortality occurrence or study termination (December 31, 2019).

Statistical analysis

Statistical analyses were performed using R software version 4.3.0 and SPSS (IBM) version 27. The participant characteristics were stratified according to the DI-GM quartiles. Numerical variables are expressed as mean ± standard deviation, and categorical data are expressed as proportion (%) and frequency distribution. For continuous measurements, the nonparametric Kruskal-Wallis test was used for comparative analysis, and for inter-group frequency comparison, the Pearson χ2 test was used. Three progressively adjusted Cox proportional hazards models were constructed to assess the relationship between DI-GM and death outcomes. Model 1: Crude model without covariates; Model 2: Demographic-adjusted model controlling for age, gender, and race/ethnicity; Model 3: Multivariable-adjusted model incorporating socioeconomic (education attainment, marital status, poverty-income ratio) and lifestyle factors (BMI, smoking, alcohol consumption, physical activity) alongside clinical variables (hypertension, coronary heart disease, stroke, cancer, insulin usage status, total cholesterol). For missing values, we adopt a multiple interpolation method based on the chain equation of the Bayesian framework. Nonlinear associations between DI-GM scores and mortality endpoints were evaluated using restricted cubic splines (RCS) with three prespecified knots, modeled within the multivariable-adjusted Cox regression framework. Stratified analyses across clinically relevant subgroups were conducted using interaction term assessments to detect potential effect modifications. Sensitivity evaluations were performed by reanalyzing complete-case datasets (excluding observations with missing covariates), thereby confirming the robustness of primary findings against missing data assumptions. Statistically significant was a p value < 0.05.

Result

Participant baseline characteristics

In this study, a total of 8,409 participants were included, with a mean age of 59.32 years (±14.76). The vast majority of all participants were non-Hispanic White people, of whom 51.83% were male (Table 1). Compared to the lowest group (Q1), groups with older ages, higher numbers of non-Hispanic White people, and higher education levels were concentrated in the higher DI-GM groups. However, we also observed a significant decrease in obesity, smoking, and heavy drinking rates with the increase of DI-GM, indicating a potential association between healthy living and elevated DI-GM. In the DI-GM group, there was no statistically significance differences in gender, marital status, physical activity, prevalence of hypertension, prevalence of coronary heart disease, prevalence of stroke, and insulin usage status.

Table 1

VariableDI-GMp
Q1Q2Q3Q4
Age, years, mean (SD)56.32 ± 15.3457.70 ± 14.9959.00 ± 14.9562.07 ± 13.68<0.001
TC, mean (SD)4.88 ± 1.144.96 ± 1.224.93 ± 1.204.88 ± 1.170.065
Gender, n (%)0.061
Male735 (51.83)1,037 (53.12)1,124 (53.27)1,462 (49.91)
Female683 (48.17)915 (46.88)986 (46.73)1,467 (50.09)
Race, n (%)<0.001
Mexican-American223 (15.73)398 (20.39)419 (19.86)443 (15.12)
Other Hispanic151 (10.65)224 (11.48)236 (11.18)338 (11.54)
Non-Hispanic White people521 (36.74)671 (34.38)828 (39.24)1,246 (42.54)
Non-Hispanic Black397 (28.00)486 (24.90)447 (21.18)536 (18.30)
Other races126 (8.89)173 (8.86)180 (8.53)366 (12.50)
Education, n (%)<0.001
Below high school457 (32.23)661 (33.86)736 (34.88)845 (28.85)
High school373 (26.30)467 (23.92)483 (22.89)649 (22.16)
Above high school588 (41.47)824 (42.21)891 (42.23)1,435 (48.99)
Marital, n (%)0.989
No spouse/partner/divorced/single564 (39.77)776 (39.75)837 (39.67)1,175 (40.12)
Married/cohabiting854 (60.23)1,176 (60.25)1,273 (60.33)1754 (59.88)
Smoking, n (%)<0.001
Do not smoke705 (49.72)960 (49.18)1,052 (49.86)1,573 (53.70)
Smoking415 (29.27)601 (30.79)696 (32.99)977 (33.36)
Now smoking298 (21.02)391 (20.03)362 (17.16)379 (12.94)
Hypertension, n (%)0.212
No478 (33.71)664 (34.02)745 (35.31)951 (32.47)
Yes940 (66.29)1,288 (65.98)1,365 (64.69)1978 (67.53)
BMI, n (%)<0.001
Normal <25189 (13.33)289 (14.81)325 (15.40)526 (17.96)
0verweight 25–30.0368 (25.95)586 (30.02)624 (29.57)949 (32.40)
Obesity> 30861 (60.72)1,077 (55.17)1,161 (55.02)1,454 (49.64)
Drinking, n (%)<0.001
No alcohol297 (20.94)397 (20.34)471 (22.32)612 (20.89)
Low/moderate alcohol consumption703 (49.58)1,014 (51.95)1,115 (52.84)1707 (58.28)
Heavy drinking418 (29.48)541 (27.72)524 (24.83)610 (20.83)
PIR, n (%)<0.001
≤1.00374 (26.38)466 (23.87)530 (25.12)544 (18.57)
1.00–3.00665 (46.90)915 (46.88)979 (46.40)1,263 (43.12)
≥3.00379 (26.73)571 (29.25)601 (28.48)1,122 (38.31)
Physical activity, n (%)0.095
Low physical activity1,009 (71.16)1,353 (69.31)1,528 (72.42)2,117 (72.28)
High physical activity409 (28.84)599 (30.69)582 (27.58)812 (27.72)
Coronary heart disease, n (%)0.226
Yes111 (7.83)150 (7.68)186 (8.82)268 (9.15)
No1,307 (92.17)1802 (92.32)1924 (91.18)2,661 (90.85)
Stroke, n (%)0.629
Yes97 (6.84)149 (7.63)154 (7.30)197 (6.73)
No1,321 (93.16)1803 (92.37)1956 (92.70)2,732 (93.27)
Cancer, n (%)0.002
Yes184 (12.98)242 (12.40)273 (12.94)463 (15.81)
No1,234 (87.02)1710 (87.60)1837 (87.06)2,466 (84.19)
Insulin usage status, n (%)0.167
Using196 (13.82)280 (14.34)310 (14.69)371 (12.67)
Not using1,222 (86.18)1,672 (85.66)1800 (85.31)2,558 (87.33)
DM, n (%)0.401
Diabetes988 (69.68)1,400 (71.72)1,481 (70.19)2037 (69.55)
Prediabetes430 (30.32)552 (28.28)629 (29.81)892 (30.45)

Participant baseline characteristics.

Numerical variables were summarized using mean ± SD, with statistical comparisons employing nonparametric Kruskal-Wallis tests. Categorical variables were presented as counts (percentages) analyzed through Pearson’s χ2 tests.

Correlation between DI-GM and all-cause and cardiovascular mortality

During the average 77.39-month follow-up, there were 1,430 all-cause deaths in 8409 participants, including 381 deaths due to cardiovascular disease. Multivariable-adjusted Cox proportional hazards regression models were used to assess the mortality risk associations with DI-GM scores. (Table 2) In Model 1 (unadjusted model), DI-GM was not significantly associated with all-cause mortality and cardiovascular mortality (p > 0.05). In Model 2 (adjusted for demographic factors), each 1-unit increment in DI-GM levels corresponded to a 9% diminished risk of all-cause mortality (HR = 0.91, 95% CI 0.88–0.94) and 13% decreased likelihood of cardiovascular-specific mortality (HR = 0.87, 95% CI 0.82–0.94), both meeting conventional statistical significance (p < 0.001). Participants in Q4 showed a 30% lower hazard ratio for all-cause mortality than those in Q1 (HR = 0.70, 95% CI 0.60–0.82; trend p < 0.001). Similarly, the Q4 group demonstrated a 35% reduced risk of cardiovascular mortality relative to the Q1 group (HR = 0.65, 95% CI 0.48–0.89, trend p < 0.001). In Model 3 (the fully adjusted model), per 1-unit increment in DI-GM concentration, multivariable analysis revealed statistically significant risk attenuation: all-cause mortality showed an 8% diminished hazard (HR = 0.92, 95% CI 0.89–0.95), while cardiovascular death exhibited an 11% decreased likelihood (HR = 0.89, 95% CI 0.83–0.95), both with p < 0.001. Participants in Q4 demonstrated a 26% lower all-cause mortality hazard relative to their Q1 counterparts (HR = 0.74, 95% CI 0.63–0.87; trend p < 0.05), with cardiovascular mortality showing comparable risk reduction (HR = 0.70, 95% CI 0.52–0.96; trend p < 0.05). In the complete model that underwent full adjustment, BGMS demonstrated a remarkably negative correlation with both all-cause mortality risk and cardiovascular mortality risk (p < 0.001). Conversely, UGMS was no significantly association with either all-cause mortality or cardiovascular mortality (p > 0.05).

Table 2

VariableModel 1Model 2Model 3
HR (95%CI)p-valueHR (95%CI)p-valueHR (95%CI)p-value
All-cause death
DI-GM0.99 (0.96,1.03)0.6980.91 (0.88,0.94)<0.0010.92 (0.89,0.95)<0.001
DI-GM (Quartile)
Q 11.00 (Reference)1.00 (Reference)1.00 (Reference)
Q 20.98 (0.83,1.16)0.8220.93 (0.79,1.10)0.4180.95 (0.80,1.13)0.548
Q 30.96 (0.82,1.14)0.6660.82 (0.69,0.96)0.0160.80 (0.68,0.94)0.008
Q 40.99 (0.85,1.16)0.9450.70 (0.60,0.82)<0.0010.74 (0.63,0.87)<0.001
P for Trend0.987<0.001<0.001
BGMS0.94 (0.90,0.98)0.0030.86 (0.82,0.90)<0.0010.89 (0.85,0.93)<0.001
UGMS1.07 (1.02,1.13)0.0040.99 (0.94,1.04)0.7560.98 (0.93,1.03)0.400
Cardiovascular death
DI-GM0.96 (0.90,1.03)0.2250.87 (0.82,0.94)<0.0010.89 (0.83,0.95)<0.001
DI-GM (Quartile)
Q 11.00 (Reference)1.00 (Reference)1.00 (Reference)
Q 21.10 (0.80,1.52)0.5471.05 (0.76,1.45)0.7621.10 (0.80,1.51)0.567
Q 30.92 (0.66,1.27)0.5990.77 (0.56,1.07)0.1210.75 (0.54,1.04)0.087
Q 40.93 (0.69,1.26)0.6580.65 (0.48,0.89)0.0060.70 (0.52,0.96)0.025
P for Trend0.351<0.0010.001
BGMS0.89 (0.82,0.97)0.0100.82 (0.75,0.89)<0.0010.86 (0.78,0.94)<0.001
UGMS1.06 (0.96,1.17)0.2250.98 (0.89,1.08)0.6290.95 (0.86,1.05)0.347

COX regression model for the connection between DI-GM and death.

HR: Risk Ratio, CI: Confidence Interval. Model 1, unadjusted; Model 2, adjusted according to age, gender and race; Model 3, adjusted according to age, gender, race, educational attainment, marital status, BMI, PIR, hypertension, drinking, smoking, physical activity, coronary heart disease, stroke, cancer, insulin use status and total cholesterol.

Detection of nonlinear outcomes between DI-GM and mortality

To assess potential non-linear associations, restricted cubic spline (RCS) modeling was implemented within the fully adjusted Cox proportional hazards framework (Model 3). (Figure 2) The increase in the DI-GM score was significantly and negatively correlated with the risk of all-cause mortality and cardiovascular mortality, with a primarily linear correlation (non-linear test p > 0.05). A linear negative correlation was also observed between the BGMS and all-cause and cardiovascular mortality (non-linear test p > 0.05), whereas no significant relationship was found between the UGMS and the two mortality rates. (Figure 3).

Figure 2

Two line graphs show hazard ratios with 95% confidence intervals. Graph A depicts a decreasing trend with overall p-value less than 0.001 and nonlinear p-value of 0.916. Graph B also shows a decreasing trend with overall p-value of 0.004 and nonlinear p-value of 0.722. Both graphs demonstrate hazard ratios on the y-axis and DI-GM on the x-axis, crossing the dashed line at 1.0.

The restricted cubic spline (RCS) curves for all-cause mortality (A) and cardiovascular mortality (B) in patients with diabetes or prediabetes, adjusted for age, gender, race, educational attainment, marital status, BMI, PIR, hypertension, drinking, smoking, physical activity, coronary heart disease, stroke, cancer, insulin use status and total cholesterol.

Figure 3

Four line graphs compare hazard ratios with predictor values. Graph A: Hazard ratio decreases with increasing BGMS (p < 0.001). Graph B: Hazard ratio shows a slight decrease with BGMS (p = 0.003). Graph A1: Hazard ratio remains stable across UGMS (p = 0.391). Graph B1: Hazard ratio remains stable across UGMS (p = 0.639). Shaded areas represent 95% confidence intervals.

The restricted cubic spline (RCS) curves for all-cause mortality (A) and cardiovascular mortality (B) among patients with diabetes or prediabetes, comparing Beneficial Gut Microbiota Score (BGMS) and Unfavorable Gut Microbiota Score (UGMS). The model was adjusted for age, gender, race, educational attainment, marital status, BMI, PIR, hypertension, drinking, smoking, physical activity, coronary heart disease, stroke, cancer, insulin use status and total cholesterol.

Subgroup analysis

We conducted a stratified analysis to evaluate the association between different populations and mortality rates. The findings revealed that DI-GM exhibited a consistently negative correlation with mortality across most subgroups, which was statistically significant. Furthermore, in terms of cardiovascular mortality, smoking status and race interact with DI-GM, indicating potential regulatory effects (interaction p < 0.05). (Figure 4).

Figure 4

Forest plot depicting hazard ratios (HR) and confidence intervals for various factors affecting all-cause mortality and cardiovascular mortality. Factors include coronary heart disease, stroke, cancer, insulin usage, gender, age, race, education, marital status, smoking, hypertension, BMI, drinking, PIR, and physical activity. Each factor shows HR, confidence intervals, P-values, and interaction P-values, with lines representing effect size and confidence intervals for both mortality types. The plot helps in assessing the impact of these factors on mortality risk.

Stratified analysis of mortality from diabetes or prediabetes with DI-GM. Stratified multivariable analyses were performed using Model 3, with all stratification variables systematically excluded from covariate adjustment to avoid over-adjustment bias. This methodological approach ensured that variables used for subgroup categorization were not included as confounders in respective stratified models.

Sensibility analysis

In the sensitivity analysis, 6,839 participants were included after excluding those who lacked covariate values when the baseline was excluded (Supplementary Table 2). The relationship between DI-GM and all-cause mortality and cardiovascular mortality demonstrated stability. Similar stability was observed in the associations between BGMS and UGMS and all-cause mortality and cardiovascular mortality.

Discussion

This study is pioneering in its use of the substantial sample size of the NHANES database to appraise the connection between DI-GM and survival outcomes among people with diabetes or prediabetes. Our analysis revealed an inverse dose–response relationship between DI-GM scores and the risks of all-cause and cardiovascular mortality. This association was found to be highly consistent, suggesting that relatively high DI-GM scores are linked to a lower likelihood of both types of mortality. These results underscore the clinical significance of dietary patterns that enhance microbial diversity in the context of diabetes management and mortality reduction.

Insulin resistance is a critical factor in the development and progression of diabetes and its precursor states (34, 35). Individuals with lower gut microbiome diversity tended to show more significant overall obesity and insulin resistance characteristics (36). An imbalance in intestinal flora may lead to a reduction in the number of beneficial bacteria that produce short-chain fatty acids (SCFAs), especially butyric acid, which is directly related to decreased insulin sensitivity and abnormal blood sugar control (37–39). A plethora of studies have demonstrated that the diversity of the gut microbiome plays a crucial role in maintaining optimal insulin sensitivity and mitigating insulin resistance (40). An imbalance in the gut microbiome can lead to the proliferation of harmful bacteria, such as proteobacteria, which transform choline and carnitine from food into trimethylamine (TMA). Once produced, TMA is further metabolized in the liver to form trimethylamine-N-oxide (TMAO), a compound that substantially elevates the risk of cardiovascular disease by facilitating atherosclerosis, thrombosis, and inflammatory processes (41). In addition, the metabolite of the gut microbiome, TMAO, is positively correlated with all-cause mortality and cardiovascular mortality (42). A positive association has been demonstrated between elevated TMAO levels and the increased probability of developing diabetes (43). Studies have shown a connection between dietary changes and shifts in the gut microbiome (37, 44).

Intestinal diols and lactones in urine are indirect biomarkers of intestinal microbiota diversity. DI-GM was positively correlated with the levels of intestinal diols and lactones in urine, indicating enhanced diversity of the intestinal microbiota. A higher DI-GM score indicates enhanced intestinal microbiota diversity (25). Recently, Wu et al. conducted a cross-sectional study of 21,640 people in the United States and found that higher DI-GM scores were significantly associated with a reduced risk of diabetes (29). However, there is still a scarcity of longitudinal studies that have investigated the issue of mortality in patients diagnosed with diabetes mellitus or prediabetes. According to our results, a pronounced inverse association was observed between DI-GM levels and mortality outcomes, with both all-cause and cardiovascular death risks demonstrating marked reductions (p < 0.05). This suggests that DI-GM is associated with a reduced risk of death in patients with diabetes or prediabetes. The results in RCS demonstrated a negative linear correlation between DI-GM and BGMS for all-cause and cardiovascular mortality (non-linear p > 0.05). Our research results also indicate that UGMS is negatively correlated with all-cause mortality and cardiovascular mortality in patients with diabetes or prediabetes, but the difference was no statistically significant (p > 0.05). Tindall and Shreiner et al. demonstrated that UGMS focuses on components such as red meat and refined grains, which generate uremic toxins such as TMAO through intestinal flora metabolism, activate the NLRP3 inflammatory body, and induce endothelial cell apoptosis (45, 46). In addition, a diet high in fat and sugar but low in fiber, fruits and vegetables is associated with chronic inflammation (47). In our study, there was no significant association between UGMS and mortality. This might be due to the shorter course of diabetes in the high-exposure group of UGMS in the sample, which led to the cumulative effect of chronic inflammation not being fully manifested. Dietary optimization has demonstrated efficacy in fostering the proliferation of beneficial gut microbiota, thereby reducing the risk of death, consistent with the findings of previous studies. The absence of statistical significance in the coarse model may indicate the influence of confounding factors, particularly age. Interestingly, we performed a stratified analysis and discovered that DI-GM exerted a more pronounced effect on the mortality risk among middle-aged and elderly individuals, which might be attributable to age-related decline in metabolic reserves. Zhang et al. discovered that an augmentation in the score of DI-GM was correlated with the risk of developing sarcopenia, a condition that was prevalent among middle-aged and elderly populations and is connected with inadequate metabolic reserves (48). A substantial body of research has demonstrated that the gut microbiota plays a pivotal role in the aging process. Higher DI-GM scores have been found to be associated with a reduced risk of accelerated aging (49, 50). Our results showed a significant interaction between smoking and race in the subgroup analysis. Research indicates that smoking significantly increases the risk of all-cause and cardiovascular mortality in individuals with diabetes. However, smoking cessation is associated with a lower risk and a strong positive correlation with other cardiovascular health outcomes (including heart failure and peripheral artery disease) (51–53). Therefore, it may mask the protective factors of DI-GM, leading to an increased risk of death. The prevalence of diabetes also varies by race, with the highest prevalence among Hispanics/Latinos (54, 55).

DI-GM has many potential applications in clinical practice. By quantifying the impact of diet on the gut microbiota, DI-GM can identify high-risk groups for diabetes, cardiovascular diseases and cancer (56–58). Based on the beneficial and unfavorable components of DI-GM, dietary plans are customized for patients, such as guiding prediabetic patients to adjust the proportion of dietary fiber to reduce the risk of progression (32, 35, 57, 59).

This investigation presents several notable strengths. First, as a novel dietary evaluation metric, DI-GM has been examined for its associations with mortality in populations with diabetes or prediabetes for the first time, to our knowledge. Second, the nationally representative NHANES cohort employed a multistage probability cluster sampling design, ensuring methodological rigor and population generalizability. Third, comprehensive covariate adjustments minimized confounding biases, with sensitivity analyses confirming result robustness. Several limitations warrant consideration. First, inherent methodological constraints exist in DI-GM’s current formulation, particularly regarding the inclusion criteria for emerging dietary components requiring empirical validation. Second, our analysis lacked granular data on food preparation methods, potentially influencing microbiome interactions. Third, NHANES dietary recalls omitted tea subtype specifications, possibly affecting DI-GM scoring accuracy. Future investigations should prioritize validating disputed dietary-microbiome interactions, and elucidating microbiota-mediated dietary influences on metabolic outcomes.

Conclusion

The research discovered that the DI-GM score exhibits an inverse relationship with both all-cause mortality and cardiovascular mortality among individuals with diabetes or pre-diabetes. A greater DI-GM score has been found to correlate with enhanced diversity of the gut microbiota, which is associated with a lower risk of mortality. These results highlight the importance of consuming foods that are beneficial to the gut microbiota in the prevention and control of diabetes and its early stages.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

Author contributions

WS: Data curation, Formal analysis, Funding acquisition, Methodology, Writing – original draft. DL: Data curation, Writing – original draft. ZXi: Data curation, Writing – original draft. LJ: Data curation, Writing – original draft. YT: Data curation, Writing – original draft. ZXu: Methodology, Writing – original draft. LL: Methodology, Writing – original draft. SY: Methodology, Writing – original draft. XF: Methodology, Writing – original draft. YW: Writing – review & editing. QW: Writing – review & editing, Funding acquisition.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the Youth Teacher Training Project of Education Department of Anhui Province (No. JWFX2024028) and Anhui Province Key Clinical Specialist Construction Programs.

Acknowledgments

We sincerely express our gratitude to the participants and investigators of the NHANES study for their invaluable contributions, which have provided significant support and assistance to our research endeavors.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The authors declare that no Gen AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2025.1621277/full#supplementary-material

Abbreviations

NHANES, National Health and Nutrition Examination Survey; DI-GM, Dietary Index of Gut Microbiota; BGMS, Beneficial Gut Microbiota Score; UGMS, Unfavorable Gut Microbiota Score; RCS, Restricted cubic splines; SCFA, Short-chain fatty acids; FPG, Fasting plasma glucose; 2h-OGTT, 2-hour oral glucose tolerance test; HbA1c, Glycated hemoglobin; PIR, Family poverty income ratio; BMI, Body mass index; HR, Hazard Ratio; CI, Confidence Interval; TMAO, Trimethylamine-N-oxide; ADA, American Diabetes Association.

References

  • 1.

    GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet. (2023) 402:203–34. doi: 10.1016/S0140-6736(23)01301-6

  • 2.

    American Diabetes Association. 2 Classification and diagnosis of diabetes: standards of medical Care in Diabetes-2021. Diabetes Care. (2021) 44:S15–s33. doi: 10.2337/dc21-S002

  • 3.

    Echouffo-TcheuguiJBPerreaultLJiLDagogo-JackS. Diagnosis and Management of Prediabetes: a review. JAMA. (2023) 329:1206–16. doi: 10.1001/jama.2023.4063

  • 4.

    ColagiuriS. Definition and classification of diabetes and prediabetes and emerging data on phenotypes. Endocrinol Metab Clin N Am. (2021) 50:319–36. doi: 10.1016/j.ecl.2021.06.004

  • 5.

    CosentinoFGrantPJAboyansVBaileyCJCerielloADelgadoVet al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. (2020) 41:255–323. doi: 10.1093/eurheartj/ehz486

  • 6.

    RaghavanSVassyJLHoYLSongRJGagnonDRChoKet al. Diabetes mellitus-related all-cause and cardiovascular mortality in a National Cohort of adults. J Am Heart Assoc. (2019) 8:e011295. doi: 10.1161/JAHA.118.011295

  • 7.

    CaiXZhangYLiMWuJHYMaiLLiJet al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. (2020) 370:2297. doi: 10.1136/bmj.m2297

  • 8.

    TianYQiuZWangFDengSWangYWangZet al. Associations of diabetes and prediabetes with mortality and life expectancy in China: a National Study. Diabetes Care. (2024) 47:1969–77. doi: 10.2337/dca24-0012

  • 9.

    ZhuTGoodarziMO. Metabolites linking the gut microbiome with risk for type 2 diabetes. Curr Nutr Rep. (2020) 9:83–93. doi: 10.1007/s13668-020-00307-3

  • 10.

    LauWLTranTRheeCMKalantar-ZadehKVaziriND. Diabetes and the gut microbiome. Semin Nephrol. (2021) 41:104–13. doi: 10.1016/j.semnephrol.2021.03.005

  • 11.

    LeighSJMorrisMJ. Diet, inflammation and the gut microbiome: mechanisms for obesity-associated cognitive impairment. Biochim Biophys Acta Mol basis Dis. (2020) 1866:165767. doi: 10.1016/j.bbadis.2020.165767

  • 12.

    LeeCJSearsCLMaruthurN. Gut microbiome and its role in obesity and insulin resistance. Ann N Y Acad Sci. (2020) 1461:37–52. doi: 10.1111/nyas.14107

  • 13.

    AsadiAShadab MehrNMohamadiMHShokriFHeidaryMSadeghifardNet al. Obesity and gut-microbiota-brain axis: a narrative review. J Clin Lab Anal. (2022) 36:e24420. doi: 10.1002/jcla.24420

  • 14.

    WuHTremaroliVSchmidtCLundqvistAOlssonLMKrämerMet al. The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study. Cell Metab. (2020) 32:379–390.e3. doi: 10.1016/j.cmet.2020.06.011

  • 15.

    MakkiKDeehanECWalterJBäckhedF. The impact of dietary Fiber on gut microbiota in host health and disease. Cell Host Microbe. (2018) 23:705–15. doi: 10.1016/j.chom.2018.05.012

  • 16.

    PerlerBKFriedmanESWuGD. The role of the gut microbiota in the relationship between diet and human health. Annu Rev Physiol. (2023) 85:449–68. doi: 10.1146/annurev-physiol-031522-092054

  • 17.

    CanforaEEMeexRCRVenemaKBlaakEE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. (2019) 15:261–73. doi: 10.1038/s41574-019-0156-z

  • 18.

    KohAde VadderFKovatcheva-DatcharyPBäckhedF. From dietary Fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. (2016) 165:1332–45. doi: 10.1016/j.cell.2016.05.041

  • 19.

    ZhaoLZhangFDingXWuGLamYYWangXet al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. (2018) 359:1151–6. doi: 10.1126/science.aao5774

  • 20.

    ShoerSShiloSGodnevaABen-YacovOReinMWolfBCet al. Impact of dietary interventions on pre-diabetic oral and gut microbiome, metabolites and cytokines. Nat Commun. (2023) 14:5384. doi: 10.1038/s41467-023-41042-x

  • 21.

    PestoniGRiedlABreuningerTAWawroNKriegerJPMeisingerCet al. Association between dietary patterns and prediabetes, undetected diabetes or clinically diagnosed diabetes: results from the KORA FF4 study. Eur J Nutr. (2021) 60:2331–41. doi: 10.1007/s00394-020-02416-9

  • 22.

    ZhengYLeySHHuFB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. (2018) 14:88–98. doi: 10.1038/nrendo.2017.151

  • 23.

    SampsellKWangWOhlandCMagerLFPettNLowryDEet al. Exercise and prebiotic Fiber provide gut microbiota-driven benefit in a survivor to germ-free mouse translational model of breast Cancer. Cancers (Basel). (2022) 14:2722. doi: 10.3390/cancers14112722

  • 24.

    FanZLiLBuLGengZLiuS. Association between a dietary index for gut microbiota and breast cancer history in adult women: findings from NHANES 2011-2020. Front Nutr. (2025) 12:1619809. doi: 10.3389/fnut.2025.1619809

  • 25.

    KaseBELieseADZhangJMurphyEAZhaoLSteckSE. The development and evaluation of a literature-based dietary index for gut microbiota. Nutrients. (2024) 16:1045. doi: 10.3390/nu16071045

  • 26.

    LiYPanFShenX. Association of the dietary index for gut microbiota with sleep disorder among US adults: the mediation effect of dietary inflammation index. Front Nutr. (2025) 12:1528677. doi: 10.3389/fnut.2025.1528677

  • 27.

    MaleszaIJMaleszaMWalkowiakJMussinNWalkowiakDAringazinaRet al. High-fat, Western-style diet, systemic inflammation, and gut microbiota: a narrative review. Cells. (2021) 10:3164. doi: 10.3390/cells10113164

  • 28.

    NguyenLHMaWWangDDCaoYMallickHGerbabaTKet al. Association between sulfur-metabolizing bacterial communities in stool and risk of distal colorectal Cancer in men. Gastroenterology. (2020) 158:1313–25. doi: 10.1053/j.gastro.2019.12.029

  • 29.

    WuZGongCWangB. The relationship between dietary index for gut microbiota and diabetes. Sci Rep. (2025) 15:6234. doi: 10.1038/s41598-025-90854-y

  • 30.

    LiuJHuangS. Dietary index for gut microbiota is associated with stroke among US adults. Food Funct. (2025) 16:1458–68. doi: 10.1039/D4FO04649H

  • 31.

    XiaoYYangYGaoSZhangHWangJLinTet al. Dietary index for gut microbiota, a novel protective factor for the prevalence of chronic kidney diseases in the adults: insight from NHANES 2007-2018. Front Nutr. (2025) 12:1561235. doi: 10.3389/fnut.2025.1561235

  • 32.

    ZhangXYangQHuangJLinHLuoNTangH. Association of the newly proposed dietary index for gut microbiota and depression: the mediation effect of phenotypic age and body mass index. Eur Arch Psychiatry Clin Neurosci. (2025) 275:1037–48. doi: 10.1007/s00406-024-01912-x

  • 33.

    MacGregorKAGallagherIJMoranCN. Relationship between insulin sensitivity and menstrual cycle is modified by BMI, fitness, and physical activity in NHANES. J Clin Endocrinol Metab. (2021) 106:2979–90. doi: 10.1210/clinem/dgab415

  • 34.

    ChenZFrancoOHLamballaisSIkramMASchoufourJDMukaTet al. Associations of specific dietary protein with longitudinal insulin resistance, prediabetes and type 2 diabetes: the Rotterdam study. Clin Nutr. (2020) 39:242–9. doi: 10.1016/j.clnu.2019.01.021

  • 35.

    DongZ-HPanRYRenGYZhouMZhangBFanJLet al. A novel antidiabetic peptide GPAGAP from Andrias davidianus collagen hydrolysates: screening, action mechanism prediction and improving insulin resistance in Hep G2 cells. Food & Medicine Homology. (2024) 1:9420010. doi: 10.26599/FMH.2024.9420010

  • 36.

    Le ChatelierENielsenTQinJPriftiEHildebrandFFalonyGet al. Richness of human gut microbiome correlates with metabolic markers. Nature. (2013) 500:541–6. doi: 10.1038/nature12506

  • 37.

    ValdesAMWalterJSegalESpectorTD. Role of the gut microbiota in nutrition and health. BMJ. (2018) 361:k2179. doi: 10.1136/bmj.k2179

  • 38.

    CuiJRameshGWuMJensenETCragoOBertoniAGet al. Butyrate-producing Bacteria and insulin homeostasis: the microbiome and insulin longitudinal evaluation study (MILES). Diabetes. (2022) 71:2438–46. doi: 10.2337/db22-0168

  • 39.

    TolhurstGHeffronHLamYSParkerHEHabibAMDiakogiannakiEet al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. (2012) 61:364–71. doi: 10.2337/db11-1019

  • 40.

    RanaivoHThirionFBéra-MailletCGuillySSimonCSothierMet al. Increasing the diversity of dietary fibers in a daily-consumed bread modifies gut microbiota and metabolic profile in subjects at cardiometabolic risk. Gut Microbes. (2022) 14:2044722. doi: 10.1080/19490976.2022.2044722

  • 41.

    WitkowskiMWeeksTLHazenSL. Gut microbiota and cardiovascular disease. Circ Res. (2020) 127:553–70. doi: 10.1161/CIRCRESAHA.120.316242

  • 42.

    LiDLuYYuanSCaiXHeYChenJet al. Gut microbiota-derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis. Am J Clin Nutr. (2022) 116:230–43. doi: 10.1093/ajcn/nqac074

  • 43.

    ZhuangRGeXHanLYuPGongXMengQet al. Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: a systematic review and dose-response meta-analysis. Obes Rev. (2019) 20:883–94. doi: 10.1111/obr.12843

  • 44.

    O'KeefeSJLiJVLahtiLOuJCarboneroFMohammedKet al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun. (2015) 6:6342. doi: 10.1038/ncomms7342

  • 45.

    DinanTGCryanJF. The microbiome-gut-brain Axis in health and disease. Gastroenterol Clin N Am. (2017) 46:77–89. doi: 10.1016/j.gtc.2016.09.007

  • 46.

    TindallAMPetersenKSKris-EthertonPM. Dietary patterns affect the gut microbiome-the link to risk of Cardiometabolic diseases. J Nutr. (2018) 148:1402–7. doi: 10.1093/jn/nxy141

  • 47.

    ZhangZBiCWuRQuM. Association of the newly proposed dietary index for gut microbiota and constipation: a cross-sectional study from NHANES. Front Nutr. (2025) 12:1529373. doi: 10.3389/fnut.2025.1529373

  • 48.

    ZhangJGuoJZhangJLiuHZhouLChengCet al. The mediating role of biological age in the association between dietary index for gut microbiota and sarcopenia. Front Immunol. (2025) 16:1552525. doi: 10.3389/fimmu.2025.1552525

  • 49.

    AnSQinJGongXLiSDingHZhaoXet al. The mediating role of body mass index in the association between dietary index for gut microbiota and biological age: a study based on NHANES 2007-2018. Nutrients. (2024) 16:4164. doi: 10.3390/nu16234164

  • 50.

    LingZLiuXChengYYanXWuS. Gut microbiota and aging. Crit Rev Food Sci Nutr. (2022) 62:3509–34. doi: 10.1080/10408398.2020.1867054

  • 51.

    PanAWangYTalaeiMHuFB. Relation of smoking with Total mortality and cardiovascular events among patients with diabetes mellitus: a Meta-analysis and systematic review. Circulation. (2015) 132:1795–804. doi: 10.1161/CIRCULATIONAHA.115.017926

  • 52.

    AuneDSchlesingerSNoratTRiboliE. Tobacco smoking and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Eur J Prev Cardiol. (2019) 26:279–88. doi: 10.1177/2047487318806658

  • 53.

    AlnimaTMeijerRISpronkHMHWarléMCateH. Diabetes- versus smoking-related thrombo-inflammation in peripheral artery disease. Cardiovasc Diabetol. (2023) 22:257. doi: 10.1186/s12933-023-01990-6

  • 54.

    JosephJJOrtizRAcharyaTGoldenSHLópezLDeedwaniaP. Cardiovascular impact of race and ethnicity in patients with diabetes and obesity: JACC focus seminar 2/9. J Am Coll Cardiol. (2021) 78:2471–82. doi: 10.1016/j.jacc.2021.06.020

  • 55.

    ChengYJKanayaAMAranetaMRGSaydahSHKahnHSGreggEWet al. Prevalence of diabetes by race and ethnicity in the United States, 2011-2016. JAMA. (2019) 322:2389–98. doi: 10.1001/jama.2019.19365

  • 56.

    LiDRLiuBQLiMHQinYLiuJCZhengWRet al. Dietary index for gut microbiota and risk of gastrointestinal cancer: a prospective gene-diet study. Nutr J. (2025) 24:81. doi: 10.1186/s12937-025-01151-3

  • 57.

    QuHYangYXieQYeLShaoY. Linear association of the dietary index for gut microbiota with insulin resistance and type 2 diabetes mellitus in U.S. adults: the mediating role of body mass index and inflammatory markers. Front Nutr. (2025) 12:1557280. doi: 10.3389/fnut.2025.1557280

  • 58.

    ZhengHLiHKongLZhangXGaoYHuLet al. Association of dietary patterns with cognitive function in older people: results from the Chinese longitudinal healthy longevity survey. Medicine Advances. (2023) 1:246–59. doi: 10.1002/med4.35

  • 59.

    AbbigeriMBThokchomBSinghSRBhaviSMHariniBPYarajarlaRB. Antioxidant and anti-diabetic potential of the green synthesized silver nanoparticles using Martynia annua L. root extract. Nano Trans Med. (2025) 4:100070–12. doi: 10.1016/j.ntm.2025.100070

Summary

Keywords

dietary index of gut microbiota (DI-GM), diabetes, prediabetes, all-cause mortality, cardiovascular mortality

Citation

Song W, Liu D, Xing Z, Jiang L, Tang Y, Xu Z, Li L, Yan S, Fu X, Wang Y and Wu Q (2025) Association of the newly proposed dietary index for gut microbiota and all-cause and cardiovascular mortality among individuals with diabetes and prediabetes. Front. Nutr. 12:1621277. doi: 10.3389/fnut.2025.1621277

Received

30 April 2025

Accepted

31 July 2025

Published

14 August 2025

Volume

12 - 2025

Edited by

Wenlong Sun, Shandong University of Technology, China

Reviewed by

Rocio Guizar-Heredia, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico

Piao Shenghua, Guangdong Pharmaceutical University, China

Muhammad Hassan Sarfraz, Government College University, Faisalabad, Pakistan

Meng-Yao Li, Shanghai Jiao Tong University, China

Updates

Copyright

*Correspondence: Qiwen Wu,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics